In a regulatory filing, Krystal Biotech disclosed that its CEO Krish Krishnan sold 50K shares of common stock on January 17th in a total transaction size of $4.04M.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
- EC grants Krystal Biotech orphan designation for KB407 for CF treatment
- Krystal Biotech PDUFA delay ‘a minor setback,’ says Chardan
- H.C. Wainwright sees no further delay after Krystal’s B-VEC PDUFA date revision
- Krystal Biotech announces FDA 3-month extension of BLA PDUFA date